Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.
- 1 January 2001
- journal article
- review article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 11 (3) , 235-246
- https://doi.org/10.1023/a:1011917021686
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.2001
- Dalteparin in combination with abciximab during percutaneous coronary interventionAmerican Heart Journal, 2001
- Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina PectorisCirculation, 2001
- Local Delivery of Enoxaparin to Decrease Restenosis After Stenting: Results of Initial Multicenter TrialCirculation, 2001
- Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicineAmerican Heart Journal, 2000
- Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated heparin?Journal of the American College of Cardiology, 2000
- Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectorisThe American Journal of Cardiology, 1999
- Combination therapy with tirofiban and enoxaparin in acute coronary syndromesInternational Journal of Cardiology, 1999
- Relation Between Activated Clotting Time During Angioplasty and Abrupt ClosureCirculation, 1996
- Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinaseJournal of the American College of Cardiology, 1988